Watch our capabilities presentation to learn how our integrated CDMO solutions accelerate immune cell therapy development from early-phase to commercial readiness.
March 17, 2025 (Research Triangle Park, NC): Kincell Bio, a leader in cell therapy development and manufacturing, is excited to announce the appointment of Larry...
Kincell Bio’s Bruce Thompson outlines how to streamline the path from candidate selection to Investigational New Drug (IND) application.
New contract reinforces Kincell Bio’s commitment to long-term partnerships to address development and GMP manufacturing support for engineered cellular therapies. Gainesville, Florida (September 16, 2024)...
Read MoreNew contract reinforces Kincell Bio’s commitment to long-term partnerships to address development and GMP manufacturing support for engineered cellular therapies. Durham, North Carolina (September 4,...
Read MoreKincell Bio’s Jessica Carmen outlines how savvy cell therapy innovators can avoid expensive corner-cutting with strategic spending choices.
We conducted a study assessing the
effect of three commercially available cGMP grade medias and their influence on T-cell phenotype.
Serial entrepreneur has created, built and sold three CDMOs GAINESVILLE, Fla. – May 21, 2024 – Kincell Bio, LLC (“Kincell”), a technology-forward contract development and...
Read More
1622 NW 55th Place
Gainesville, FL 32653
20 TW Alexander Dr, Suite 130
RTP, NC 27703
